For media queries, please contact:
Rachel Steinhardt, Director of Communications
[+1] 212 450 1582 - Business hours, EST (GMT -5 hours)
Email: Rachel Steinhardt
News
May 09, 2013
MAPPING THE EMBRYONIC EPIGENOME
Researchers elucidate how precise chemical modifications across the genome turn genes on and off during early human development—and how those mechanisms are disrupted in cancer
May 9, 2013, New York, NY and San Diego, CA - A large, multi-institutional research team involved in the NIH Epigenome Roadmap Project has published a sweeping analysis in the current issue of the journal Cellof how genes are turned on and off to direct early human development. Led by Bing Ren of the Ludwig Institute for Cancer Research, Joseph Ecker of The Salk Institute for Biological Studies and James Thomson of the Morgridge Institute for Research, the scientists also describe novel genetic phenomena likely to play a pivotal role not only in the genesis of the embryo, but that of cancer as well. Their publicly available data, the result of more than four years of experimentation and analysis, will contribute significantly to virtually every subfield of the biomedical sciences.
April 25, 2013
REVIVING A FOE OF CANCER
New research reveals how the tumor suppressor p53 is shut down in metastatic melanoma - and how it can be revived
April 25, 2013, New York, NY and Oxford, UK - Cancer cells are a problem for the body because they multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong. One protein that keeps healthy cells from behaving this way is a tumor suppressor named p53. This protein stops potentially precancerous cells from dividing and induces suicide in those that are damaged beyond repair. Not surprisingly, p53’s critical function is disrupted in most cancers.
